You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,080,580

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,080,580 protect, and when does it expire?

Patent 8,080,580 protects SEGLUROMET, STEGLATRO, and STEGLUJAN, and is included in three NDAs.

This patent has sixty patent family members in forty-nine countries.

Summary for Patent: 8,080,580

Patent landscape, scope, and claims:

Title:	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Abstract:	Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001##
Inventor(s):	Mascitti; Vincent (Groton, CT), Collman; Benjamin M. (Ledyard, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	12/546,306
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,080,580
Patent Claim Types: see list of patent claims	Use; Composition; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 8,080,580

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-002	Dec 19, 2017		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-001	Dec 19, 2017		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-004	Dec 19, 2017		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-003	Dec 19, 2017		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	STEGLATRO	ertugliflozin	TABLET;ORAL	209803-001	Dec 19, 2017	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	STEGLATRO	ertugliflozin	TABLET;ORAL	209803-002	Dec 19, 2017	AB	RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
Msd Sub Merck	STEGLUJAN	ertugliflozin; sitagliptin phosphate	TABLET;ORAL	209805-001	Dec 19, 2017		RX	Yes	No	⤷ Subscribe	⤷ Subscribe	Y	Y		AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,080,580

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2334687	⤷ Subscribe	122018000070	Germany	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	300943	Netherlands	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	LUC00079	Luxembourg	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	2018C/027	Belgium	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	PA2018510	Lithuania	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	CA 2018 00025	Denmark	⤷ Subscribe
European Patent Office	2334687	⤷ Subscribe	30/2018	Austria	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.